Biotheus builds on ADC pact with Hansoh; Novartis expands in Singapore; Astellas leaves Cartesian deal
Plus, news about Biocon Biologics, Eris Lifesciences, Aprea Therapeutics and Pi Health:
Biotheus expands ADC deal with Hansoh Pharmaceutical: Under the extended pact, Hansoh will get a license to use an anti-EGFR/cMet bispecific antibody developed by Biotheus to create its own ADC product. Biotheus could receive up to RMB 5 billion ($694 million) in upfront and milestones payments, as well as tiered royalties on net sales. — Ayisha Sharma
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
